Clinical Trial Detail

NCT ID NCT01918306
Title GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors Vanderbilt-Ingram Cancer Center
Indications

Her2-receptor negative breast cancer

Therapies

Cisplatin

Cisplatin + Pictilisib

Age Groups: adult

Additional content available in CKB BOOST